Get the Stockscreener App
5.57
5.59%
-0.33
After Hours:
5.75
0.18
+3.23%
Briacell Therapeutics Corp stock is traded at $5.57, with a volume of 160.56K.
It is down -5.59% in the last 24 hours and down -34.98% over the past month.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
See More
Previous Close:
$5.90
Open:
$5.99
24h Volume:
160.56K
Relative Volume:
1.84
Market Cap:
$16.41M
Revenue:
-
Net Income/Loss:
$-16.60M
P/E Ratio:
-6.2584
EPS:
-0.89
Net Cash Flow:
$-23.48M
1W Performance:
-8.56%
1M Performance:
-34.98%
6M Performance:
-49.48%
1Y Performance:
-91.36%
1-Day Range:
$5.35
$6.5361
1-Week Range:
$5.1164
$6.5361
52-Week Range:
$5.1164
$65.55
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Name
Briacell Therapeutics Corp
Sector
Industry
Phone
(604) 921-1810
Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Compare BCTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
5.57 | 16.41M | 0 | -16.60M | -23.48M | -0.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-22 | Initiated | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Stock (BCTX) Latest News
BriaCell Therapeutics (OTCMKTS:BCTXF) Shares Down 2.3% – Here’s What Happened - Defense World
BriaCell Announces Completion of 15:1 Share Consolidation - GlobeNewswire
BriaCell Completes 15:1 Share Consolidation for Nasdaq Compliance - TipRanks
BriaCell's Major Stock Transformation: 44M Shares Become 2.9M in Critical Nasdaq Move - StockTitan
BriaCell Therapeutics (NASDAQ:BCTXW) Shares Down 11.4% – Here’s Why - Defense World
BriaCell Therapeutics (NASDAQ:BCTX) Shares to Reverse Split on Wednesday, January 29th - Defense World
Certain Options of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 10-JAN-2025. - Marketscreener.com
BriaCell Therapeutics (CVE:BCT) Stock Price Down 3.8% – Here’s Why - Defense World
BCTX stock touches 52-week low at $0.46 amid sharp annual decline - Investing.com
BriaCell Therapeutics (OTCMKTS:BCTXF) Shares Up 2.7% – Here’s Why - Defense World
BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025 - The Manila Times
BriaCell Announces Proposed Effective Date of Share Consolidation - The Manila Times
BriaCell Announces 15:1 Share Consolidation to Maintain Nasdaq Listing Compliance - StockTitan
Bullish BriaCell Therapeutics Insider Buying Worth US$5.52m Yet To Pay Off - Simply Wall St
Insider Purchases Worth US$5.52m See Losses As BriaCell Therapeutics Market Value Drops To CA$40m - Yahoo Finance
BCTXBriacell Therapeutics Corp. Common Shares Latest Stock News & Market Updates - StockTitan
BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures - GlobeNewswire
BriaPro Therapeutics Corp. Announces Availability of Annual - GlobeNewswire
BriaPro Therapeutics Announces Digital Voting Process for 2025 Annual Meeting Amid Postal Strike - StockTitan
Vancouver biotech BriaCell to raise US$5.5 million in share offering - Business in Vancouver
BriaCell Therapeutics Corp. Reports Earnings Results for the First Quarter Ended October 31, 2024 - Marketscreener.com
BriaCell Therapeutics Corp. (BCTX) reports earnings - Quartz
BriaCell Therapeutics Reports Quarterly Financial Loss - TipRanks
BriaCell Therapeutics (OTCMKTS:BCTXF) and AbbVie (NYSE:ABBV) Head-To-Head Comparison - Defense World
BriaCell Therapeutics’ (BCTX) “Buy” Rating Reiterated at HC Wainwright - Defense World
BriaCell Therapeutics Announces Closing of $5.5 Million Public Offering - The Manila Times
BriaCell Therapeutics (CVE:BCT) Trading Down 3.8% – Here’s What Happened - Defense World
Briacell Therapeutics Corp (BCTX-Q) QuotePress Release - The Globe and Mail
BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ - GlobeNewswire
BriaCell's Groundbreaking Cancer Treatment Shows Promise in Converting 'Cold' Tumors to 'Hot' in Clinical Trial - StockTitan
BriaCell Therapeutics Announces $5.5M Public Offering with 5-Year Warrants at $0.75 Per Share - StockTitan
BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering - The Manila Times
BriaCell announces public offering of shares and warrants By Investing.com - Investing.com South Africa
Certain Warrants of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 12-DEC-2024. - Marketscreener.com
BriaCell announces public offering of shares and warrants - Investing.com
BriaCell Therapeutics Announces Proposed Public Offering - GlobeNewswire
BriaCell Therapeutics Launches Public Offering of Shares and Warrants to Fund Growth Initiatives - StockTitan
BriaCell Presents Unprecedented Overall Survival Data in - GlobeNewswire
BriaCell's Cancer Immunotherapy Shows Breakthrough Results: Doubles Survival in Phase 2 Trial - StockTitan
BriaCell Shows Promising Survival Data in Cancer Trial - TipRanks
HC Wainwright Analysts Lift Earnings Estimates for TSE:BCT - Defense World
HC Wainwright Reiterates Buy Rating for BriaCell Therapeutics (NASDAQ:BCTX) - Defense World
BriaCell Therapeutics (NASDAQ:BCTXW) Trading Up 12.2% – Here’s Why - Defense World
H.C. Wainwright reiterates Buy rating on Briacell Therapeutics stock - Investing.com
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend - Benzinga
BriaCell Receives Green-Light from Data Safety Monitoring Board for Its Phase 3 Study in Metastatic Breast Cancer - Marketscreener.com
BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer - GlobeNewswire
BriaCell's Phase 3 Cancer Trial Clears Key Safety Review for Breast Cancer Treatment - StockTitan
BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive - GlobeNewswire
BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer - The Manila Times
BriaCell's Breast Cancer Therapy Shows 13.4-Month Survival Rate in Phase 2 Trial | BCTX Stock News - StockTitan
Briacell Therapeutics Corp Stock (BCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):